Biopharmaceutical Venture Capital Trends: Coronavirus Disease (COVID-19) Company Impact Report
Summary
This report examines the impact of the COVID-19 pandemic on venture capital deals for biopharmaceutical companies. This analysis is critical to understanding how the outbreak of COVID-19 impacted investments and how those VC deal trends may impact current and future venture capital investments.
Scope
This report is required reading for -
Reasons to Buy
Summary
This report examines the impact of the COVID-19 pandemic on venture capital deals for biopharmaceutical companies. This analysis is critical to understanding how the outbreak of COVID-19 impacted investments and how those VC deal trends may impact current and future venture capital investments.
Scope
This report is required reading for -
- Investors that want to understand how COVID-19 has impacted VC deals in the biopharmaceutical industry as well as identifying companies that may be due for a round of financing in upcoming months
- Companies that are due to raise venture capital in the near future and need to consider 2020 VC trends into their capital raising strategies.
- Large pharma companies with investment groups or BD teams looking for partnership opportunities where companies may be in need of financing with changing VC trends during the COVID-19 pandemic.
Reasons to Buy
- Monthly trends of VC deals by value and volume; including an analysis of monthly VC activity in China versus U.S. during the spread of the diease
- Analyzes how COVID-19 has shifted investment trends by deal value, round, and therapeutic area
- Assessment of investors activity level in biopharmaceutical VC deals prior to and during the COVID-19 pandemic
- Identify biopharmaceutical companies that may be looking for rounds of financing and how they may be impacted by the shifted trends in VC investment
Table of Contents
1 Executive Summary2 Table of Contents
3 Venture Capital Trends
4 Investors in Biopharmas
5 Regional Breakout
6 Companies with Venture Capital at Risk
7 Key Findings
8 Appendix
List of Tables
Table 1: Q1 2020: Top Companies by Venture Capital Amount
Table 2: Top Therapeutic Areas Receiving Venture Capital (2020)
Table 3: Most Active Investors by Deal Volume: Q1 2020
Table 4: Most Active Investors by Deal Value: Q1 2020
Table 5: 2019: Top Investors by Deal Count
Table 6: 2019 VC Invested by Region (by Recipient HQ Location)
Table 7: Companies Actively Looking to Close Venture Capital Rounds
Table 8: Biopharma Companies with Planned Series A Financing
Table 9: Sample of Biopharma Companies with Expected Series B Financing
Table 10: Sample of Biopharma Companies with Expected Series C Financing
Table 11: Sample of Biopharma Companies with Expected Series D Financing
List of Figures
Figure 1: Venture Capital Deals by Month
Figure 2: Venture Capital Deal Value 2019 FY vs. 2020 ($M)
Figure 3: Deal Volume by Series
Figure 4: Deal Value by Series
Figure 5: VC for Infectious Diseases Drugs Table
Figure 6: Top Investors by Deal Count - Q1 2020 vs. 2019
Figure 7: Spread of COVID-19
Figure 8: Venture Capital Deals in China
Figure 9: Venture Capital Deals in the US
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4d Molecular Therapeutics
- Adlai Nortye Biopharma Co Ltd.
- AIVITA Biomedical, Inc.
- Akouos Inc
- Alexandria Venture Investments
- Aligos Therapeutics Inc
- ALX Oncology Inc
- Amal Therapeutics SA
- Annexon, Inc
- Ansun BioPharma Inc
- Antiva Biosciences
- Apexigen, Inc.
- Aqualung Therapeutics Corp
- ARCH Venture Partners LP
- ARS Pharmaceuticals, Inc.
- Ascentage Pharma group
- Atomwise Inc.
- Biopact Cellular Transport Inc
- Blueberry Therapeutics Ltd.
- Boxer Capital
- BW Therapeutics LLC
- Cadent Therapeutics
- Carisma Therapeutics Inc.
- Casdin Capital LLC
- Casma Therapeutics, Inc.
- Celsense Inc
- CerFlux Inc
- Chondrial Therapeutics LLC
- Cormorant Asset Management LLC
- Cowen Healthcare Investments
- Decibel Therapeutics, Inc.
- Deerfield Management
- ElevateBio LLC
- Emulate Inc.
- EQRx Inc
- Escient Pharmaceuticals, Inc.
- Evox Therapeutics Ltd
- Fidelity Management & Research
- Foresite Capital Management LLC
- Freeline Therapeutics
- Galecto Biotech AB
- Galera Therapeutics Inc
- Generation Bio Corp
- Heartseed Inc
- Horama SA
- Hotspot Therapeutics, Inc
- Hoverink Biotechnologies Inc
- ILiAD Biotechnologies, LLC
- Immune-Onc Therapeutics, Inc.
- Immunocore Ltd
- Impact Therapeutics
- InCarda Therapeutics, Inc.
- InSightec Ltd
- Intarcia Therapeutics Inc
- Intensity Therapeutics, Inc.
- iTeos Therapeutics SA
- KAHR medical Ltd
- Kaitai Capital
- Kallyope Inc
- Kleo Pharmaceuticals Inc
- Ksq Therapeutics, Inc
- Kymera Therapeutics LLC
- Lilly Asia Ventures
- Max Biopharma Inc
- Medicxi Ventures (UK) LLP
- Metacrine, Inc.
- Minoryx Therapeutics
- Modalis Therapeutics Corporation
- Nanjing Legend Biotech Co Ltd
- NBE-Therapeutics AG
- Neuraly, Inc
- Neurana Pharmaceuticals, Inc.
- Neurotez Inc
- NMD Pharma ApS
- Nohla Therapeutics, Inc.
- Novo Holdings AS
- Oncoheroes Biosciences Inc
- OncoResponse, Inc.
- Orasis Pharmaceuticals
- Orbimed Advisors LLC
- Partner Therapeutics, Inc
- Perceptive Advisors
- Phylos Bioscience Inc
- Pliant Therapeutics Inc
- Polaris Partners LLC
- Quentis Therapeutics, Inc.
- RA Capital Management LLC
- Rakuten Medical Inc
- Rallybio, LLC
- ReAlta Life Sciences Inc
- Redmile Group LLC
- Relay Therapeutics
- RemeGen Ltd
- Rgenix, Inc
- Rheos Medicines, Inc.
- Ripple therapeutics Corp
- Rongchang Bio-Pharmaceutical Co., Ltd
- Sen-Jam Pharmaceutical LLC
- Senti Biosciences, Inc
- Sirnaomics, Inc.
- Slayback Pharma LLC
- SQZ Biotech
- StemBioSys Inc
- Surveyor Capital Ltd
- SutroVax Inc
- Synthego Corporation
- Tecnologia Regenerativa Qrem SL
- Transcenta Holding Ltd
- Vedanta Biosciences, Inc.
- Velicept Therapeutics, Inc.
- Vivo Capital LLC
- Xilio Therapeutics Inc
- XtalPi, Inc.
